Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 1396 AL 1410

Combined stimulation of the substantia nigra pars reticulata and the subthalamic nucleus is effective in hypokinetic gait disturbance in Parkinson's disease

Weiss D, Breit S, Wächter T, Plewnia C, Gharabaghi A, Krüger R.

J Neurol. 2011 Jun;258(6):1183-5. doi: 10.1007/s00415-011-5906-3. Epub 2011 Feb 2.

Parkinson's disease--the continuing search for biomarkers

Breen DP, Michell AW, Barker RA.

Clin Chem Lab Med. 2011 Mar;49(3):393-401. doi: 10.1515/CCLM.2011.080. Epub 2011 Feb 3.

Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases

Frankola KA, Greig NH, Luo W, Tweedie D.

CNS Neurol Disord Drug Targets. 2011 May;10(3):391-403. doi: 10.2174/187152711794653751.

The myosin phosphatase targeting protein (MYPT) family: a regulated mechanism for achieving substrate specificity of the catalytic subunit of protein phosphatase type 1δ

Grassie ME, Moffat LD, Walsh MP, MacDonald JA.

Arch Biochem Biophys. 2011 Jun 15;510(2):147-59. doi: 10.1016/j.abb.2011.01.018. Epub 2011 Feb 1.

Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies

International Parkinson Disease Genomics Consortium; Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simón-Sánchez J, Schulte C, Lesage S, Sveinbjörnsdóttir S, Stefánsson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW.

Lancet. 2011 Feb 19;377(9766):641-9. doi: 10.1016/S0140-6736(10)62345-8. Epub 2011 Feb 1.

Skewering the subthalamic nucleus via a parietal approach

Zrinzo L, Holl EM, Petersen EA, Limousin P, Foltynie T, Hariz MI.

Stereotact Funct Neurosurg. 2011;89(2):70-5. doi: 10.1159/000323371. Epub 2011 Feb 2.

MicroRNAs in Parkinson's disease

Harraz MM, Dawson TM, Dawson VL.

J Chem Neuroanat. 2011 Oct;42(2):127-30. doi: 10.1016/j.jchemneu.2011.01.005. Epub 2011 Feb 2.

Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine

Flood DG, Marek GJ, Williams M.

Biochem Pharmacol. 2011 Jun 15;81(12):1422-34. doi: 10.1016/j.bcp.2011.01.021. Epub 2011 Feb 3.

[Parkinsonism induced by sulpiride and veralipride: two different stories]

Martí Massó JF, Ruiz-Martínez J, Bergareche A, López de Munain A.

Med Clin (Barc). 2011 Oct 15;137(10):473-4. doi: 10.1016/j.medcli.2010.09.038. Epub 2011 Feb 4.

Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients

Gil RA, Hwynn N, Fabian T, Joseph S, Fernandez HH.

Parkinsonism Relat Disord. 2011 May;17(4):285-7. doi: 10.1016/j.parkreldis.2011.01.007. Epub 2011 Feb 5.

A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion

Westin J, Nyholm D, Pålhagen S, Willows T, Groth T, Dougherty M, Karlsson MO.

Clin Neuropharmacol. 2011 Mar-Apr;34(2):61-5. doi: 10.1097/WNF.0b013e31820b570a.

Extranigral extension of structural midbrain lesions overshadows parkinsonism

Kim HJ, Yun JY, Kim JM, Kim YK, Erm G, Kim SE, Jeon BS.

J Neural Transm (Vienna). 2011 Aug;118(8):1209-13. doi: 10.1007/s00702-011-0584-y. Epub 2011 Feb 5.

Genetic analysis of two Japanese families with progressive external ophthalmoplegia and parkinsonism

Sato K, Yabe I, Yaguchi H, Nakano F, Kunieda Y, Saitoh S, Sasaki H.

J Neurol. 2011 Jul;258(7):1327-32. doi: 10.1007/s00415-011-5936-x. Epub 2011 Feb 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias